AACR: Pfizer and Lilly CDK 4/6 inhibitors show breast cancer promise
This article was originally published in Scrip
Two investigational drugs acting on the cyclin-dependent kinase pathway have shown promising results at the American Association for Cancer Research (ACCR) meeting in San Diego, this week: Pfizer's palbociclib, and Eli Lilly's follower LY2835219.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.